دورية أكاديمية
Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022.
| العنوان: | Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022. |
|---|---|
| المؤلفون: | Foeldvari I; Hamburg Centre for Pediatric and Adolescent Rheumatology, Schön Klinik Hamburg Eilbek, Hamburg, Germany., Torok KS; University of Pittsburgh and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh, Pittsburgh, PA, USA., Antón J; Department of Pediatric Rheumatology. Hospital Sant Joan de Déu and Universitat de Barcelona, Barcelona, Spain., Blakley M; Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, IN, USA., Constantin T; Unit of Pediatric Rheumatology, Tűzoltó Street Department, Pediatric Centre, Semmelweis University, Budapest, Hungary., Cutolo M; Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology-Department of Internal Medicine and Specialties, University of Genoa and IRCCS San Martino Polyclinic Hospital, Genoa, Italy., Denton CP; UCL Division of Medicine, Royal Free London NHS Foundation Trust, London, UK., Fligelstone K; Scleroderma & Raynaud's United Kindgom (SRUK) (Research Subcommittee, Patient Research Partner), FESCA, London, UK., Hinrichs B; Children's pulmonology, Asklepios Klinik Nord - Heidberg, Hamburg, Germany., Li SC; Hackensack University Medical Center, Hackensack, NJ, USA., Maillard S; Great Ormond Street Hospital, London, UK., Marrani E; Pediatric Rheumatology Unit, Meyer Children's Hospital IRCCS, Florence, Italy., Moinzadeh P; Department of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany., Orteu CH; UCL Institute of Immunity and Transplantation, Royal Free London NHS Foundation Trust, London, UK., Pain CE; Alder Hey Children's Foundation NHS Trust, Liverpool, UK., Pauling JD; Department of Internal Medicine, Ghent University, Ghent, Belgium.; Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium and ERN ReCONNET., Pilkington C; Great Ormond Street Hospital, London, UK., Rosser F; University of Pittsburgh and University of Pittsburgh Medical Center Children's Hospital of Pittsburgh, Pittsburgh, PA, USA., Smith V; University of California, Los Angeles, CA, USA.; University of Washington, Seattle, WA, USA.; University of Florence, Florence, Italy., Furst DF; Division of Rheumatology Fellow, Geffen School of Medicine at the University of California in Los Angeles, Los Angeles, CA, USA. |
| المصدر: | Expert review of clinical immunology [Expert Rev Clin Immunol] 2024 Apr; Vol. 20 (4), pp. 387-404. Date of Electronic Publication: 2024 Jan 02. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101271248 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8409 (Electronic) Linking ISSN: 1744666X NLM ISO Abbreviation: Expert Rev Clin Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: London, UK : Future Drugs Ltd., 2005- |
| مواضيع طبية MeSH: | Scleroderma, Localized* , Scleroderma, Systemic*/drug therapy, Child ; Humans ; Consensus |
| مستخلص: | Introduction: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1,000,000 children. Currently there is only one consensus treatment guideline concerning skin, pulmonary and vascular involvement for jSSc, the jSSc SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) initiative, which was based on data procured up to 2014. Therefore, an update of these guidelines, with a more recent literature and expert experience, and extension of the guidance to more aspects of the disease is needed. Areas Covered: Treatment options were reviewed, and opinions were provided for most facets of jSSc including general management, some of which differs from adult systemic sclerosis, such as the use of corticosteroids, and specific organ involvement, such as skin, musculoskeletal, pulmonary, and gastroenterology. Expert Opinion: We are suggesting the treat to target strategy to treat early to prevent cumulative disease damage in jSSc. Conclusions are derived from both expert opinion and available literature, which is mostly based on adult systemic sclerosis (aSSc), given shared pathophysiology, extrapolation of results from aSSc studies was judged reasonable. |
| فهرسة مساهمة: | Keywords: gastrointestinal involvement; juvenile systemic sclerosis; musculoskeletal involvement; physical therapy; pulmonary involvement; skin involvement; treatment recommendations; vascular involvement |
| SCR Disease Name: | Juvenile systemic scleroderma; Juvenile-onset scleroderma |
| تواريخ الأحداث: | Date Created: 20231227 Date Completed: 20240318 Latest Revision: 20240326 |
| رمز التحديث: | 20240327 |
| DOI: | 10.1080/1744666X.2023.2298354 |
| PMID: | 38149621 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-8409 |
|---|---|
| DOI: | 10.1080/1744666X.2023.2298354 |